Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Mesothelioma 2Lung Neoplasms 2Esophageal Neoplasms 2Thymus Neoplasms 1Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 5Nivolumab 5pembrolizumab 3atezolizumab 3Radiosurgery 3pralsetinib 2pertuzumab 2cobimetinib 2cemiplimab 2amminedichloro(2-methylpyridine)platinum(II) 2alectinib 2Magnetic Resonance Spectroscopy 2Exercise 2Drug Therapy 2trastuzumab deruxtecan 1trametinib 1tepotinib 1talazoparib 1selpercatinib 1repotrectinib 1remune 1ponatinib 1pemigatinib 1pazopanib 1palbociclib 1osimertinib 1motexafin gadolinium 1montanide ISA 51 1itacitinib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × Plicamycin × Thoracic × Clear all
NCT01624090 2019-12-30

Mithramycin for Lung, Esophagus, and Other Chest Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
16 enrolled 13 charts
BreastGastrointestinalOther solid neoplasmThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡